Stock Market Update - November 25, 2025
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. CETY - Clean Energy Technologies, Inc.
Price: $2.32 | Change: +116.82% ($1.25)
CETY surged an impressive 116.82% following the announcement of a substantial $10 million Battery Energy Storage System (BESS) project in New York State. This marks Clean Energy Technologies' largest storage project to date, with the company serving as the primary contractor, responsible for everything from planning and engineering to construction and installation of the 5MW / 20MWh system. This initiative is designed to enhance grid reliability and help manage energy demand.
What makes this particularly noteworthy is how this landmark award contributes to CETY's reported contracted project backlog, now exceeding $20 million. Additionally, the company has recently been exploring energy-efficient solutions for AI data centers and crypto miners, forming partnerships for mobile power and geothermal systems. These diverse and positive developments across the clean energy sector have collectively bolstered investor confidence in CETY's growth trajectory.
2. KZIA - Kazia Therapeutics Limited
Price: $12.79 | Change: +51.36% ($4.34)
KZIA recently experienced a significant 51.36% gain, propelled by groundbreaking clinical news for its paxalisib drug program. The company announced a rare and highly encouraging development: a patient with stage IV triple-negative breast cancer (TNBC), a severe and often resistant form of breast cancer, achieved an initial immune-complete response (iCR). This outcome came after receiving a combination therapy including paxalisib, with earlier data showing an 86% tumor reduction followed by complete metabolic resolution of all lesions.
This is particularly notable because metastatic TNBC is known for being aggressive and resistant to treatment, making such a complete response a rare and significant finding. Adding to the positive sentiment, Kazia plans to discuss a potential New Drug Application (NDA) pathway with the FDA for paxalisib in newly diagnosed glioblastoma, based on promising survival signals. These developments highlight the drug's potential impact across different challenging cancers.
3. KSS - Kohl's Corporation
Price: $22.42 | Change: +42.53% ($6.69)
KSS soared with a 42.53% gain recently, catching investors' attention with a wave of positive news. The retail giant saw its stock jump after announcing better-than-expected third-quarter fiscal 2025 financial results and significantly improving its full-year outlook.
A major surprise was Kohl's reporting an adjusted earnings per share (EPS) profit of $0.10, handily beating analyst predictions of a loss. While overall sales were still down, the decline was less than anticipated, and the company also managed to increase its gross margin. Boosting confidence further, Kohl's raised its full-year earnings guidance for the second time this year.
Adding to the positive sentiment, Michael J. Bender was officially appointed as the permanent CEO, bringing much-needed leadership stability. This combination of strong financial outperformance and solidified leadership appears to have been the main catalyst for the significant rally in Kohl's stock.
4. FSHPR - Flag Ship Acquisition Corporation
Price: $0.1201 | Change: +41.55% ($0.0499)
FSHPR:NASDAQ saw a perplexing surge of 41.55% around late November 2025. Despite this significant jump for Flag Ship Acquisition Corporation rights, public news and market data from the period offered no clear catalyst.
Searches for new partnerships, financial results, or major corporate announcements specifically for FSHPR didn't reveal any event that would account for such a rapid increase. Adding to the mystery, some market data from the same timeframe even indicated a significant decline for FSHPR rights, contradicting the reported rise.
FSHPR represents rights to Flag Ship Acquisition Corporation (FSHP), a special purpose acquisition company (SPAC) focused on merger opportunities. While FSHP had announced a new merger agreement back in April 2025, this event occurred much earlier and doesn't directly explain the sudden late-November price movement, leaving the specific reason for this reported spike unclear.
5. PAVS - Paranovus Entertainment Technology Ltd.
Price: $0.8209 | Change: +41.34% ($0.2401)
PAVS surged by an impressive 41.34% on November 25, 2025, after Paranovus Entertainment Technology announced a plan to potentially raise up to $200 million. This strategic move, known as a mixed shelf offering, signals the company's intent to sell various types of securities to generate capital.
This substantial capital-raising effort is aimed at fueling PAVS's ambitious plans in AI-powered entertainment products, such as AI-driven games and apps, as well as TikTok-related e-commerce solutions. This announcement, coupled with an analyst upgrade to a "Buy" recommendation for potential short-term gains, likely contributed to the positive investor sentiment.
What makes this particularly noteworthy is PAVS's recent financial history, including weak financials and negative cash flow. For a company focused on the competitive AI entertainment sector, securing this potential funding could be a crucial step in advancing its growth strategy and turning its fortunes around.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.